Nerve Growth Factor Antagonism in Pain Management

Nerve growth factor (NGF) has emerged as a pivotal mediator of pain through its activation of high-affinity receptors on peripheral sensory neurons, leading to nociceptor sensitisation and amplified pain signalling. In many chronic pain states—particularly osteoarthritis, cancer pain and inflammatory neuropathies—elevated NGF levels correlate with increased pain intensity and functional impairment. Therapeutic antagonism of NGF employs monoclonal antibodies or small molecules to block NGF binding or to inhibit downstream signalling via its principal receptor, tropomyosin receptor kinase A (TrkA). Clinical trials of anti-NGF antibodies have demonstrated significant analgesic benefits and improved mobility, yet raised concerns regarding joint structural alterations in osteoarthritis, prompting stringent imaging-based safety strategies. Recent advances focus on refining specificity—targeting co-receptor complexes or developing reversible modulation—and exploring active immunisation approaches to achieve sustained pain relief without long-term adverse effects. Globally, NGF antagonism represents a non-opioid strategy with the potential to transform management of chronic pain, reduce reliance on traditional analgesics and improve quality of life across diverse patient populations.

Research from Nature Portfolio

Recent studies have revealed that the NGF receptor p75NTR is upregulated in osteochondral cells during osteoarthritis, where it attenuates NF-κB activation to support bone formation and suppress pathological bone resorption. Loss of this receptor in animal models intensifies inflammation, disrupts BMP–SMAD1 signalling and accelerates joint damage, suggesting that careful modulation of NGF pathways is essential not only for analgesia but also for maintaining tissue repair mechanisms in diseased joints.

Nerve Growth Factor Antagonism in Pain Management publication trend

The graph below shows the total number of articles in nerve growth factor antagonism in pain management across all publications each year (not limited to Nature Index journals).

Technical terms

Nerve Growth Factor (NGF): A neurotrophin that binds to sensory-neuron receptors to promote survival, growth and sensitisation of pain pathways.

Tropomyosin Receptor Kinase A (TrkA): The high-affinity tyrosine kinase receptor for NGF, whose activation triggers intracellular signalling leading to nociceptor sensitisation.

Nociceptor: A specialised sensory neuron that detects potentially harmful thermal, mechanical or chemical stimuli and conveys pain signals to the central nervous system.

Neuropilin 1 (NRP1): A transmembrane coreceptor that enhances or modulates NGF–TrkA complex formation and downstream signal transduction.

Monoclonal Antibody Antagonist: A laboratory-produced antibody designed to bind NGF or its receptor with high specificity, preventing receptor activation and subsequent pain signalling.

References

1. Nerve growth factor receptor limits inflammation to promote remodeling and repair of osteoarthritic joints. Nature Communications (2024).
2. Blocking the tropomyosin receptor kinase A (TrkA) receptor inhibits pain behaviour in two rat models of osteoarthritis. Annals of the Rheumatic Diseases (2015).
3. Role of imaging for eligibility and safety of a-NGF clinical trials. Therapeutic Advances in Musculoskeletal Disease (2023).
4. Active immunisation targeting nerve growth factor attenuates chronic pain behaviour in murine osteoarthritis. Annals of the Rheumatic Diseases (2019).
5. Tanezumab for Patients with Osteoarthritis of the Knee: A Meta-Analysis. PLOS ONE (2016).